Anti-TGF beta 2 Antibody, Non-Fucosylated (BioBet-456ZP) (CAT#: BioBet-456ZP) Datasheet

TGFB2

TGFB2 Gene(Protein Coding)


Transforming Growth Factor Beta 2

This gene encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. Ligands of this family bind various TGF-beta receptors leading to recruitment and activation of SMAD family transcription factors that regulate gene expression. The encoded preproprotein is proteolytically processed to generate a latency-associated peptide (LAP) and a mature peptide, and is found in either a latent form composed of a mature peptide homodimer, a LAP homodimer, and a latent TGF-beta binding protein, or in an active form consisting solely of the mature peptide homodimer. The mature peptide may also form heterodimers with other TGF-beta family members. Disruption of the TGF-beta/SMAD pathway has been implicated in a variety of human cancers. A chromosomal translocation that includes this gene is associated with Peters' anomaly, a congenital defect of the anterior chamber of the eye. Mutations in this gene may be associated with Loeys-Dietz syndrome. This gene encodes multiple isoforms that may undergo similar proteolytic processing. [provided by RefSeq, Aug 2016]

Lerdelimumab;Trabio;CAT-152;6B1;Anti-TGF-Beta-2;Trabio;Trabio;CAT-152;TGFB2;transforming growth factor, beta 2;transforming growth factor beta-2;G-TSF;cetermin;polyergin;BSC-1 cell growth inhibitor;glioblastoma-derived T-cell suppressor factor;TGF-beta2;M

Extracellular region or secreted

Diseases associated with TGFB2 include Loeys-Dietz Syndrome 4 and Holt-Oram Syndrome.

Its related pathways are Cell adhesion_Plasmin signaling and Degradation of the extracellular matrix.

1.Transforming growth factor-2 preprotein: Delay associated peptide (LAP) and transforming growth factor-2 (tgf-2) chain precursors, which constitute the regulatory and active subunits of tgf-2, respectively. 2.It is necessary to store the transforming growth factor-2 (tgf-2) chain in a latent state in the extracellular matrix (similarity). It associates non-covalently with tgf-2, and regulates its activation (through similarity) through interaction with "environmental molecules" that control tgf-2 activation (such as LTBP1 and LRRC32/GARP). 3.Transforming growth factor-2: a multifunctional protein that regulates various processes such as angiogenesis and heart development. Activation into the mature form follows different steps: After the cleavage of the preprotein in the Golgi apparatus, the delayed-associated peptide (LAP) and transforming growth factor-2 (tgf -2) chains remain non-covalently linked, making tgf -2 in the extracellular matrix Inactivation during storage (due to similarity). At the same time, the LAP chain interacts with "environmental molecules", such as LTBP1 and LRRC32/GARP, to control the activation of tgf-2 and keep it latent in the extracellular environment (similar). Once activated after the release of LAP, tgf-2 acts by binding to tgf-receptors (TGFBR1 and TGFBR2) and conducts signals (through similarity).

The precursor is cleaved into mature TGF-beta-2 and LAP, which remains non-covalently linked to mature TGF-beta-2 rendering it inactive.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG4

BioBet-456ZP

Human

Human

ADCC-enhanced Lerdelimumab is a non-fucosylated anti-TGF beta 2 therapeutic biobetter antibody.

Glaucoma surgery

Glaucoma surgery